ArticleMetabolic brain disease2026
Activation of mitophagy via miR-223/NLRP3 axis ameliorates dopaminergic neuronal damage in parkinson's disease.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Parkinson’s disease (PD) is a major neurodegenerative disorder. MiR-223 as a potential biomarker for Parkinson’s disease, NLRP3-driven neuroinflammation, and their interaction represent a significant research gap. This study aimed to investigate the role of mitophagy activation by targeting miR-223/NLRP3 interaction to alleviate dopamine neuronal damage in PD. Firstly, in vivo, rats were divided into sham, PD model, and intervention groups (PD + agomiR-NC or PD + agomiR-223). AgomiRs were delivered via targeted intracranial injection. Neurobehavioral assessments, histopathological analysis, mitochondrial ultrastructure quantification, and neuroinflammatory marker detection were performed to evaluate PD progression and mitophagy. Second, in vitro, MPTP-treated PC12 cells were divided into seven groups and transfected with either miR-223 mimic, mimic negative control (NC), oe-NLRP3, or oe-NC. MiR-223 and NLRP3 expression, cell viability, mitochondrial morphology/function, and inflammatory responses were analyzed to elucidate the molecular mechanisms linking miR-223/NLRP3 signaling to mitophagy activation. First, in vivo experiments demonstrated that PD + agomiR-223 rats exhibited significant improvements in motor performance, improved motor function and exploratory behavior, attenuated histopathological brain damage, and preserved mitochondrial ultrastructure compared to the PD group. Additionally, agomiR-223 treatment markedly decreased neuroinflammatory markers in brain tissues. Then, in vitro experiments showed that after miR223 mimic treatment, PC12 cell viability, mitophagy level and inflammation level were improved compared with MPTP group, while oe-NLRP3 addition offset these effects. Additionally, autophagy activator, rapamycin, reversed the impact of oe-NLRP3 on MPTP+ miR223 mimic treated cells. These findings suggest miR-223 alleviates dopaminergic neuronal damage in PD by inhibiting NLRP3 inflammasome activation and promoting mitophagy.
Indexed as
Identifiers
41870730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.